SCHEMBL4279863

SCHEMBL4279863

COC(C(=O)O)=C(c1ccccc1)C(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.48
SRC P12931 1/20 0.44
KMT2A Q03164 4/20 0.42
GAA P10253 1/20 0.42
ALDH1A1 P00352 4/20 0.41
NPSR1 Q6W5P4 3/20 0.41
RAB9A P51151 3/20 0.41
HTT P42858 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
ELANE P08246 2/20 0.41
HPGD P15428 1/20 0.41
PTGS2 P35354 2/20 0.41
CES1 P23141 2/20 0.41
PTGS1 P23219 1/20 0.41
POLB P06746 1/20 0.41
KDM4E B2RXH2 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
MEN1 O00255 2/20 0.40
MAPT P10636 2/20 0.40
NPC1 O15118 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL755236 0.80 TSHR (0.41) TSHRSRCKMT2AGAAALDH1A1
SCHEMBL4884737 0.80 KCNK3 (0.43) KMT2AGAAALDH1A1SMN1; SMN2HPGD
SCHEMBL27941236 0.78 TSHR (0.48) TSHRSRCKMT2AGAAALDH1A1
SCHEMBL17428 0.76 TSHR (0.47) TSHRSRCKMT2AGAAALDH1A1
SCHEMBL31119064 0.76 TSHR (0.47) TSHRSRCKMT2AGAAALDH1A1
SCHEMBL15673297 0.76 SMN1; SMN2 (0.44) TSHRKMT2AGAAALDH1A1NPSR1
SCHEMBL6576791 0.76 TSHR (0.56) TSHRSRCKMT2AALDH1A1RAB9A
SCHEMBL6472265 0.75 CES1 (0.45) TSHRKMT2AGAAALDH1A1NPSR1
SCHEMBL1173261 0.75 PGR (0.43) TSHRKMT2AGAAALDH1A1NPSR1
SCHEMBL1576740 0.75 TSHR (0.54) TSHRSRCKMT2AGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3154510-B1 COMPOSITION FOR PROTECTING KERATIN MATERIALS FROM SUN OREAL (FR) 2022-01-19 EP claimed
EP-1866033-B1 SUNSCREEN AEROSOL SPRAY ENSIGN LABORATORIES PTY LTD (AU) 2017-04-19 EP claimed
US-20190038538-A1 RNA COMPLEXES THAT INHIBIT MELANIN PRODUCTION OLIX PHARMACEUTICALS, INC. (KR) 2019-02-07 US disclosed
US-10064801-B2 RNA complexes that inhibit melanin production OLIX PHARMACEUTICALS, INC. (KR) 2018-09-04 US disclosed
WO-2017017523-A1 RNA COMPLEXES THAT INHIBIT MELANIN PRODUCTION OLIX PHARMACEUTICALS, INC. (KR) 2017-02-02 WO disclosed
US-20170027837-A1 RNA COMPLEXES THAT INHIBIT MELANIN PRODUCTION OLIX PHARMACEUTICALS, INC. (KR) 2017-02-02 US disclosed
US-9012418-B2 Topical administration of at least one double-stranded RNA oligonucleotide (dsRNA) L'OREAL (FR) 2015-04-21 US disclosed
EP-1309532-B1 METHOD FOR OBTAINING COCOA BEAN POLYPHENOL EXTRACTS, RESULTING EXTRACTS AND USES THEREOF BARRY CALLEBAUT AG (CH) 2013-02-27 EP disclosed
US-20090117063-A1 Topical administration of at least one double-stranded RNA oligonucleotide (dsRNA) DURANTON ALBERT 2009-05-07 US disclosed
US-7368144-B2 Method for obtaining cocoa bean polyphenol extracts, resulting extracts and uses thereof BARRY CALLEBAUT FRANCE (FR) 2008-05-06 US disclosed
US-20070258920-A1 Process for obtaining polyphenol extracts from cocoa beans, the resulting extracts and uses thereof BARRY CALLEBAUT AG (CH) 2007-11-08 US disclosed
EP-0998445-B1 COMPOSITIONS BASED ON RESVERATROL CAUDALIE (FR) 2003-10-01 EP disclosed
US-6572882-B1 Having in particular a high stability as regards air and light; esterification CAUDALIE (FR) 2003-06-03 US disclosed
EP-1309532-A1 METHOD FOR OBTAINING COCOA BEAN POLYPHENOL EXTRACTS, RESULTING EXTRACTS AND USES THEREOF Barry Callebaut AG. (CH) 2003-05-14 EP disclosed
WO-2002014251-A1 METHOD FOR OBTAINING COCOA BEAN POLYPHENOL EXTRACTS, RESULTING EXTRACTS AND USES THEREOF BARRY CALLEBAUT AG. (CH) 2002-02-21 WO disclosed
EP-0703954-B1 POLYPHENOL DERIVATIVE COMPOSITIONS AND PREPARATION THEREOF BERKEM SA (FR) 2001-12-19 EP disclosed
EP-0998445-A1 COMPOSITIONS BASED ON RESVERATROL Caudalie (FR) 2000-05-10 EP disclosed
WO-1999003816-A1 COMPOSITIONS BASED ON RESVERATROL CAUDALIE (FR) 1999-01-28 WO disclosed
EP-0703954-A1 POLYPHENOL DERIVATIVE COMPOSITIONS AND PREPARATION THEREOF BERKEM (FR) 1996-04-03 EP disclosed
WO-1994029404-A1 POLYPHENOL DERIVATIVE COMPOSITIONS AND PREPARATION THEREOF BERKEM (FR) 1994-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090117063-A1 Topical administration of at least one double-stranded RNA oligonucleotide (dsRNA) DCLRE1B, POLRMT, ADAR TSHR 3322/4885SRC 4099/4885KMT2A 3634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.